<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00639054</url>
  </required_header>
  <id_info>
    <org_study_id>959593931/Emil Hermansen</org_study_id>
    <secondary_id>H-B-2007-117</secondary_id>
    <nct_id>NCT00639054</nct_id>
  </id_info>
  <brief_title>The Molecular Characterization of Multiple Myeloma at Relapse</brief_title>
  <acronym>MM-FISH/DNA</acronym>
  <official_title>The Molecular Characterization of Multiple Myeloma at Relapse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Herlev Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zealand University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Naestved Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Agnes og Poul Friis Fond</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Carl og Ellen Hertzs Legat til Dansk Læge- og Naturvidenskab</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dagmar Marshalls Fond</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Danish Cancer Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Direktør Jacob Madsen og hustru Olga Madsens Fond</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Elna og Jørgen Fagerholt Pedersens Kræftforskningsfond</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eva og Henry Frænkels Mindefond</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fabrikant Einar Willumsens Mindelegat</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fonden til Lægevidenskabens Fremme</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Grosserer M. Brogaard og Hustrus Mindefond</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Højmosegård-Legatet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Janssen-Cilag, S.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Karen A. Tolstrups fond</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Krista og Viggo Petersens Fond</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Købmand Sven Hansen og hustru Ina Hansens Fond</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Meta og Håkon Baggers Fond</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Reinholdt W. Jorck og hustrus Fond</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observational study investigating prognostic factors in newly diagnosed and relapsed multiple
      myeloma patients by use of clinical data, biochemical markers (blood samples), cytogenetic
      markers and gene expression profiling (myeloma cells from fresh bone marrow samples).
      Enabling future genetic studies by establishing a biobank of bone marrow and peripheral blood
      samples.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multiple myeloma (MM) is an incurable cancer. The disease can often be brought to a halt with
      chemotherapy which in younger patients is accompanied by stem cell transplantation. But the
      disease relapses almost invariably. Cytogenetic changes in the myeloma cells can serve as
      prognostic markers. Accordingly, 25% of the patients show changes associated with a prognosis
      so poor that they should probably receive experimental treatment right from the start.
      Nevertheless, a part of these patients survive much longer than expected. Thus, the prognosis
      must depend on additional genetic events.

      The aim of this project is to widen the investigators knowledge of the nature, chronology and
      prognostic value of the genetic events in MM in order to improve the risk stratification of
      the patients and hence the choice of treatment. Using cytogenetics (interphase FISH) and
      molecular biological analyses (SNP, GEP, miRNA) the investigators will study the changes in
      the myeloma cells. The investigators will search for genetic and clinical differences between
      patients within the same cytogenetic group and between patients at diagnosis and at relapse.
      The study population will consist of 100 newly diagnosed patients and 100 relapse patients
      included prospectively over a 2-year period in a cooperation between the four departments of
      hematology in Zealand, Denmark.

      Hypotheses:

        1. Early relapse depends on a) molecular defects in the myeloma cells detectable with FISH,
           GEP, SNP and/or miRNA analyses, and b) the acquisition of new mutations resulting in
           chemotherapy resistance and increased prolific capacity.

        2. The progressive reduction of event free survival seen with every relapse until the
           disease turns refractory can be explained by selection of critical mutations.

        3. The cytogenetic changes associated with poor prognosis represent a heterogenous group of
           patients in whom the responsible genetic events remain unknown.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Molecular characteristics (by FISH, SNP, GEP, miRNA)</measure>
    <time_frame>0-3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event free survival (EFS)</measure>
    <time_frame>0-10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>0-10 years</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">134</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Newly diagnosed patients</arm_group_label>
    <description>Newly diagnosed high-dose therapy candidates. Participation means bone marrow examination (donating 7.5 ml of fresh bone marrow) and blood samples (24 ml of peripheral blood) for biochemical and genetic analyses regarding multiple myeloma, and granting access to clinical data relating to multiple myeloma.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Relapse patients</arm_group_label>
    <description>Formerly high-dose treated patients with progressive disease. Participation means bone marrow examination (donating 7.5 ml of fresh bone marrow) and blood samples (24 ml of peripheral blood) for biochemical and genetic analyses regarding multiple myeloma, and granting access to clinical data relating to multiple myeloma.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <description>Healthy blood and bone marrow donors. Participation means bone marrow examination (donating 7.5 ml of fresh bone marrow) for genetic analyses serving to compare normal bone marrow with bone marrow from multiple myeloma patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bone marrow examination</intervention_name>
    <description>7.5 ml of iliac crest bone marrow drawn in addition to diagnostic samples.</description>
    <arm_group_label>Newly diagnosed patients</arm_group_label>
    <arm_group_label>Relapse patients</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood samples</intervention_name>
    <description>24 ml of cubital vein blood drawn in addition to diagnostic samples.</description>
    <arm_group_label>Newly diagnosed patients</arm_group_label>
    <arm_group_label>Relapse patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Peripheral whole blood Bone marrow
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed and/or treated at departments of hematology. Healthy controls.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients newly diagnosed with multiple myeloma and at the same time eligible for high
             dose chemotherapy and autologous stem cell transplantation

          -  patients with multiple myeloma experiencing relapse after high dose chemotherapy and
             autologous stem cell transplantation

        Exclusion Criteria:

          -  for newly diagnosed patients: age or comorbidity preventing high dose chemotherapy and
             autologous stem cell transplantation,

          -  for all patients: age below 18, physical or psychological incapability to give an
             informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>N Emil U Hermansen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Gimsing, MD, DMSc</last_name>
    <role>Study Chair</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Annette J Vangsted, MD, DMSc</last_name>
    <role>Study Chair</role>
    <affiliation>Zealand University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mette K Andersen, MD, DMSc</last_name>
    <role>Study Chair</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Finn C Nielsen, MD, DMSc</last_name>
    <role>Study Chair</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dan Kristensen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Naestved Hospital, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nielsaage T Clausen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Herlev Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Multiple Myeloma Research Laboratory, Dept Hematology, Cph Univ Hosp Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <state>Capital Region</state>
        <zip>DK-2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 11, 2008</study_first_submitted>
  <study_first_submitted_qc>March 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2008</study_first_posted>
  <last_update_submitted>January 6, 2016</last_update_submitted>
  <last_update_submitted_qc>January 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>N. Emil U. Hermansen</investigator_full_name>
    <investigator_title>Ph.D student</investigator_title>
  </responsible_party>
  <keyword>classification</keyword>
  <keyword>diagnosis</keyword>
  <keyword>genetics</keyword>
  <keyword>mortality</keyword>
  <keyword>pathology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

